GlaxoSmithKline (GSK)

<b>GlaxoSmithKline</b> (<a href=&quot;http://www.zacks.com/stock/quote/gsk&quot;>GSK</a>) reported third quarter income of $0.92 per American Depository Share (ADS), 3 cents below the Zacks Consensus Estimate. The company reported earnings of $0.94 in the year-ago period. Third quarter revenue increased 3%. <p> While the company&#39;s diversified base and presence in different geographical areas should help support revenues, we remain concerned about future growth prospects given the patent challenges being faced by several of Glaxo&#39;s products. With several products expected to lose exclusivity and the swine flu opportunity likely to miss expectations, we expect the company&#39;s topline to remain under pressure in the coming quarters. <p> Glaxo&#39;s pipeline needs to deliver in order to make up for lost revenues and any development or regulatory setbacks would be a major disappointment for the company. We are downgrading the stock to Underperform with a target price of $37.

Comments

Leave a Reply